
- Unveiling the threat: Characterization of Clostridioides difficile Infection in 1
- the Northwest Region of Buenos Aires between 2019-2023 and Associated 2
- Risk Factors redefined through a Meta-Analysis 3
- Angela María Barbero<sup>1,2,#</sup>, Nicolás Diego Moriconi<sup>1,#</sup>, Sabina Palma<sup>1,2,#</sup>, Josefina 4
- 5
- Celano<sup>1</sup>, María Gracia Balbi<sup>3</sup>, Lorenzo Sebastián Morro<sup>1</sup>, María Martina Calvo Zarlenga<sup>4</sup>, Jorgelina Suárez<sup>3,5</sup>, María Guadalupe Martínez<sup>3</sup>, Mónica Graciela 6
- Machain<sup>3</sup>, Carlos Gabriel Altamiranda<sup>4</sup>, Gabriel Erbiti<sup>4,5</sup>, Rodrigo Emanuel 7
- Hernández Del Pino<sup>1,2, \(\zeta\)</sup>, Virginia Pasquinelli<sup>1,2, \(\frac{\pi}{\sigma}\).</sup> 8
- 9 1 Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del
- Noroeste de la Provincia de Buenos Aires (UNNOBA). B6000DNE, Buenos Aires, 10
- Argentina. 11
- 2 Centro de Investigaciones y Transferencias del Noroeste de la Provincia de 12
- 13 Buenos Aires (CIT NOBA), UNNOBA-Universidad Nacional de San Antonio de
- Areco (UNSAdA)-Consejo Nacional de Investigaciones Científicas y Técnicas 14
- 15 (CONICET). Buenos Aires, Argentina.
- 3 Servicio de Laboratorio, Sala de Microbiología, Hospital Interzonal General de 16
- Agudos (HIGA) Dr. Abraham F. Piñeyro, Junín, Buenos Aires, Argentina 17
- 4 Clínica Centro Médico Privado SRL, Junín, Buenos Aires, Argentina 18
- 5 Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA). 19
- B6000DNE, Buenos Aires, Argentina. 20
- <sup>#</sup> Angela María Barbero, Nicolás Diego Moriconi and Sabina Palma share first 21
- 22 authorship.
- 23 <sup>5</sup> Rodrigo Emanuel Hernández Del Pino Rodrigo and Virginia Pasquinelli share the
- 24 last authorship.
- \*Corresponding author: virpasquinelli@gmail.com, Tel: +5492364582417, Address: 25
- Coronel Borges 379, Junín (Postal Code 6000), Buenos Aires, Argentina. 26
- 27 Conflict of interest. The authors declare that the research was conducted in the
- absence of any commercial or financial relationships that could be construed as a 28
- potential conflict of interest. 29
- 30 1 in 5 diarrheas is caused by *C. difficile* in the Northwest region of Buenos Aires,
- Argentina. One third of the cases were community-acquired and involved toxigenic 31
- strains. Comparison through meta-analysis identified known and also new risk 32
- 33 factors.

# **Abstract**

34

Clostridioides difficile stands as the leading cause of hospital acquired enteric 35 36 infection in developed countries. In Argentina, the epidemiology of *Clostridioides* difficile infection (CDI) is currently poorly characterized. Therefore, we conducted a 37 retrospective case-control study evaluating the prevalence of CDI in 249 stool 38 39 samples collected between 2019 and 2023 in the Northwest region of Buenos 40 Aires. The presence of *C. difficile* was detected by combining three techniques (EIA, PCR and toxigenic culture) in a diagnostic algorithm. Clinical and 41 42 demographic data from patients was also analyzed to identify CDI-associated risk factors. 1 in 5 patients presented C. difficile as the etiological agent of diarrhea and 43 the 80% of CDI+ cases carried toxigenic strains, with a third of cases acquired in 44 the community. Age ≥69 years, previous use of antibiotics, previous hospitalization 45 and previous episodes of CDI emerged as predisposing factors for CDI in our study 46 cohort. Blood parameters such as an elevated number of leukocytes and platelets, 47 a decreased basophil count, and an increased urea concentration were identified 48 49 as indicators of CDI. We also carried out a systematic review and a meta-analysis where we contrasted our results with 39 studies selected from different countries 50 around the world. At the global level, the meta-analysis highlighted advanced age, 51 52 previous consumption of antibiotics and previous hospitalization as CDI risk factors and the leukocyte count as an indicator of CDI. These results emphasize the 53 importance of epidemiological studies and reveal crucial information for healthcare 54 55 decision-making regarding CDI.

- Keywords: C. difficile, epidemiology, risk factors, meta-analysis
- 57 Running title: Risk factors and meta-analysis of CDI



Chronic kidney

disease

Leukocytosis

Heart

diseases

# Introduction

Clostridioides difficile infection (CDI) is considered as the most frequent hospital-acquired disease 1,2. Since 2019, the Centers for Disease Control (CDC) have identified C. difficile as an "urgent threat", with the immediate need to implement prevention and control actions 3. C. difficile is a Gram positive, anaerobic and spore-forming bacterium that causes intestinal damage primarily through the production of two main toxins: toxin A (TcdA) and toxin B (TcdB) 4. These toxins play a crucial role in the pathogenesis of CDI by damaging the cells lining the gut. CDI can be life-threatening, ranging from mild diarrhea to pseudomembranous colitis and causing nearly 500,000 cases per year in the United States <sup>5</sup>. 

CDI is also a major economic burden to the health care systems, which is closely linked to the high recurrence rates of this infection. Although standard treatments resolve CDI in most cases, up to 35% of CDI-treated patients will experiment a recurrence of the disease with aggravated symptoms <sup>5</sup>. Common therapy for CDI includes antibiotics such as metronidazole for mild cases and vancomycin or fidaxomicin for moderate to severe cases <sup>6</sup>. Therapies with the human antibody bezlotoxumab against C. difficile toxin B or Fecal Microbiota Transplant (FMT) to restore the balance of the microbiome have been recommended to treat or prevent recurrences <sup>7,8</sup>. 

Regarding global epidemiology, while healthcare-associated CDI has declined in recent years, the incidence of community-acquired CDI is on the rise <sup>9–14</sup>. The main transmission route for *C. difficile* is through direct Person-to-Person contact by the fecal-oral route <sup>15</sup>. *C. difficile* spores constitute the main form of resistance and can persist in the environment for long periods <sup>16,17</sup>. Then, contaminated surfaces, food or water, as well as asymptomatic carriers, are typical sources of community transmission <sup>18–20</sup>.

Several risk factors are associated with the development of CDI. The use of antimicrobials with emphasis on broad-spectrum antibiotics, has been described as the most significant risk factor for CDI <sup>21,22</sup>. These antibiotics can disrupt the normal balance of bacteria in the gastrointestinal tract, generating dysbiosis and so allowing *C. difficile* overgrow in the gut. Hospitalization in healthcare facilities and advanced age, which can be related to weakened immune systems and a higher likelihood of residing in healthcare settings, also constitute important risk factors <sup>22</sup>. The use of stomach acid regulators, such as proton pump inhibitors (PPIs) and H2 blockers, has been associated with an increased risk of CDI <sup>23</sup>; however, this is still under debate. Previous episodes of CDI increase the risk of recurrence <sup>24</sup>. Finally, several underlying health conditions that could compromise the immune system could contribute to increased susceptibility or severity of the infection. Comorbidities such as Inflammatory Bowel Disease (IBD) <sup>25</sup>, Crohn's disease <sup>25</sup>, ulcerative colitis <sup>25</sup>, diabetes <sup>26</sup> and chronic kidney disease (CKD) <sup>27</sup> can enhance the risk of CDI.

- 100 Certain clinical procedures (e.g. chemotherapy treatments and gastrointestinal
- 101 surgery), malnutrition or enteral nutrition, organ transplantation along with
- immunosuppressive medications and blood disorders may also elevate the risk of
- 103 CDI <sup>28,29</sup>.
- Understanding geographical variations in prevalence by studying CDI epidemiology
- and risk factors is essential for preventing, controlling, and managing the infection.
- In Latin America, and particularly in Argentina, comprehensive epidemiological
- data on CDI are limited. It has been reported that patients with diarrhea are not
- routinely tested for *C. difficile* in developing countries and, when tested, very often
- only the enzyme immunoassay (EIA) is used 30-32. This could lead to an
- underestimation in the diagnosis and high economic burdens for the health system.
- Our retrospective study (2019-2023) assesses the prevalence of *C. difficile* among
- 112 health care centers of the Northwest region of Buenos Aires, Argentina.
- Furthermore, with the aim to characterize our study cohort, we analyzed the
- demographic and clinical data of the patients and we conducted a meta-analysis to
- compare our findings with global reports.

# Methodology

116

117

128

# **Human Samples and Participating Institutions**

- The research was carried out in accordance with the Declaration of Helsinki (2013)
- and approved by the UNNOBA (Universidad Nacional del Noroeste de la Provincia
- de Buenos Aires) Ethics Committee (COENOBA).
- 121 Fecal samples from hospitalized adult patients with diarrhea were collected after
- obtaining informed consents and frozen at -20 °C until use. The samples were
- derived from the following health-care centers: Hospital Interzonal General de
- 124 Agudos (HIGA) Abraham Félix Piñeyro, Clínica Centro Médico Privada SRL and
- 125 Clínica IMEC. Samples received between January 1, 2019 and December 31,
- 2023 from Sanitary Region III of Buenos Aires, Argentina (Supplementary Fig. 1)
- were included in this analysis.

### **Patients characterization**

- The presence of *C. difficile* was determined in the fecal samples using a diagnostic
- algorithm (Supplementary Fig. 2) as recommended by Crobach et al. in 2016 <sup>33</sup>.
- Briefly, three tests were used in a retrospective approach: Enzyme immunoassay
- 132 (EIA, CoproStripTM C. difficile GDH + Toxin A + Toxin B (Savyon® Diagnostics
- Ltd)), Polymerase Chain Reaction from stool samples (PCR, Tag Phire Tissue
- Direct PCR Master Mix (Thermo Fisher)) and Toxigenic culture (stool culture in
- 135 CHROMAgar<sup>TM</sup> C. difficile plates + PCR from isolated C difficile colonies).
- Patients were defined as CDI+ or CDI- and clinical, demographic and blood
- parameters were evaluated (**Table 1**).
- 138 CDI classifications by setting of acquisition and severity were defined according to
- the Infectious Diseases Society of America (IDSA) criteria <sup>34</sup>.

Clinical-demographical parameters	Blood parameters	
Age	Leukocytes (cells/mm <sup>3</sup> )	
Biological Sex	Neutrophils (cells/mm <sup>3</sup> )	
Previous hospitalization	Monocytes (cells/mm <sup>3</sup> )	
Previous consumption of Antibiotics	Lymphocytes (cells/mm <sup>3</sup> )	
Antibiotics use during hospitalization	Eosinophils (cells/mm <sup>3</sup> )	
Presence of comorbidities	Basophils (cells/mm³)	

Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm <sup>3</sup> )
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

Table 1. Clinical, demographic and blood parameters evaluated in CDI+ and CDIpatients.

# Meta-analysis design

- 144 A bibliographic search was carried out using PubMed and Google Scholar
- databases in addition to the Al SciSpace tool. The reports that fulfilled the definition
- criteria of cases and controls were selected. The meta-analysis workflow is
- summarized in Fig. 4.

140

143

148

### Statistical Analysis

- For clinical, demographic and blood parameters comparisons, parametric t-test or
- non-parametric Mann-Whitney test for unpaired samples were used. Fisher's exact
- test was used to analyze the frequency distribution of qualitative/nominal variables.
- Data was analyzed using GraphPad Prism 8.0.1 software (San Diego, CA, USA)
- and p values < 0.05 were considered statistically significant.
- For the meta-analysis, the "Metafor" package from RStudio (2023.06.1+524
- version) was used 35. The Odds Ratio (OR, for categorical variables) and the
- 156 Standardized Mean Difference (SMD, for continuous variables) were calculated
- and a REML (Random Effect Maximum Likelihood) model was employed. Models
- with a p value <0.05 were considered as potential predictors of CDI incidence risk.

# **Results and Discussion**

159

160

195

196

197

# **CDI prevalence in Northwest Buenos Aires**

- In Argentina, studies and reports on CDI are scarce and heterogeneous <sup>36–39</sup>. In
- order to contribute to a better understanding of the disease, we conducted a
- retrospective analysis of 249 fecal samples received between 2019-2023 from
- Sanitary Region III of Buenos Aires.
- We determined *C. difficile* as the causal agent of one in five diarrheas (21.29%)
- (Fig. 1 a) and we detected that more than the 80% of the patients were infected
- with toxigenic strains; indicated by the presence of *C. difficile* Toxin B in the stool
- samples (Fig. 1 b). This percentage was similar to the worldwide reported
- prevalence, where CDI is the underlying cause of 15 to 20% of diarrhea associated
- with the use of antibiotics 40.
- 171 When analyzing the cases on an annual basis, the frequency of CDI ranged
- around 20% from 2019 to 2023 (Fig. 1 c). Interestingly, the highest incidence in
- our study cohort was observed during 2020, duplicating the percentage of CDI+
- cases compared to the rest of the years (Fig. 1 c). In relation to this, the COVID-19
- pandemic brought about the preventive use of broad-spectrum antibiotics to avoid
- bacterial coinfections; which could be associated with the increase in detection 41-
- 177 <sup>44</sup>. Nevertheless, CDI detection could have been impacted by the decrease in the
- number of tests, a fact that was corroborated in multiple studies carried out during
- the early stages of the pandemic 45-47. Additionally, there could also be an
- underestimation of CDI cases 48,49 since SARS-CoV-2 frequently causes
- gastrointestinal symptoms similar to those of C. difficile <sup>50</sup>.
- 182 Regarding the severity of the diarrhea, all infected patients had a moderate
- classification (Fig. 1 d). Importantly, the majority of CDI infections occurred in the
- 184 community setting (56.41%) (Fig. 1 e). 33.33% of the patients presented with
- 185 community-acquired CDI, 23.08% with community-acquired CDI associated with
- healthcare environments, and the remaining 43.59% of the patients were hospital-
- acquired (Fig. 1 e). This is particularly notable, since the epidemiology of CDI has
- changed in the last two decades. The 027 strain, responsible for clinical outbreaks
- in the early 2000s <sup>51</sup>, has recently decreased its incidence in part due
- 190 fluoroguinolones restriction, prevention measures and to improvements in
- 191 detection tests that have allowed a better characterization of the circulating
- ribotypes <sup>52–56</sup>. Additionally, an increase in strains associated with community
- infection (e.g. 078, 014 in Europe and 106 in the US) has been reported in recent
- 194 years, with community-acquired cases rising above 40% <sup>11,57–59</sup>.




Figure 1. CDI prevalence in Northwestern Buenos Aires.

249 stool samples were evaluated using the diagnostic algorithm. a) Donut graph showing positive, negative and discordant results for the presence of *C. difficile*. b) Donut graph showing the percentage of toxigenic strains (presence of Toxin B) detected in the stool samples. c) CDI+ and CDI- results classified on an annual basis from 2019 to 2023. d) CDI classification. e) CDI classification by setting of acquisition.

#### **Risk factors**

After classifying the patients as CDI+ or CDI-, we determined the risk factors that could be involved in the prevalence of CDI.

As seen in **Fig. 2 a**, we found significant differences in the age of CDI+ and CDI-populations, with the CDI+ patients presenting a higher average age (CDI+: mean = 72 years vs. CDI-: mean = 65 years). By using a ROC curve analysis, we established a cut-off point of 69 years for advanced age as a risk factor in our cohort **(Fig. 2 b)**. Elderly patients have a greater probability of receiving broad-spectrum antibiotics, being hospitalized or staying longer in hospital settings partly due to the presence of comorbidities <sup>60,61</sup>.

- 218 With age, the immune system decreases its functions and also older individuals
- develop inflammageing, which could impact in the resolution of the infection; a fact
- that was observed for neutrophils <sup>62</sup> and serum IgG against *C. difficile* toxins <sup>63–65</sup>.
- Regarding biological sex, no differences were found for the proportion of males
- and females between both patient populations (Fig. 2 c).
- 223 Consumption of antibiotics in the 3 months prior to the diagnosis of CDI, as well as
- previous hospitalizations and infections with *C. difficile*, could be considered risk
- factors that predisposes to CDI in our study cohort (Fig. 2 d, e and f). Hospitals
- and healthcare facilities are common environments for C. difficile transmission
- since they can be easily colonized by spores that persist on surfaces for months
- 228 <sup>66,67</sup>. Previous consumption of antibiotics is directly related to the dysbiosis of the
- microbiota that enables the colonization of *C. difficile* and is typically consider as
- the main risk factor for CDI <sup>68,69</sup>. Some antibiotics, such as clindamycin, broad-
- spectrum penicillins, cephalosporins and fluoroquinolones alter the microbiota to a
- greater extent than others <sup>68,70,71</sup>. When analyzing the families of antibiotics
- consumed by CDI+ patients, we observed that 56.52% had taken some kind of
- penicillin prior to diagnosis (Fig. 2 g).
- 235 On the other hand, the consumption of proton pump inhibitors (PPI) prior to
- diagnosis and the presence of comorbidities did not show significant differences
- between CDI- and CDI+ patients (Fig. 2 h and i). Fig. 2 j shows a breakdown of
- the comorbidities reported in the patients under study. Although they were
- 239 analyzed individually, no substantial variations were found between the CDI+ and
- 240 CDI- population for any of them.

245

- No differences were found regarding the variables referring to the evolution of
- patients during admission to health centers such as hospitalization in common floor
- or ICU, need for ICU, shock and death (Supplementary Fig. 3).




Figure 2. CDI associated risk factors.

Evaluation of risk factors associated with CDI. a) Age (years), b) ROC curve to establish the age cut-off point, c) biological sex, d) prior antibiotics (ATB) consumption, e) prior hospitalization, f) prior CDI, g) antibiotic breakdown by family, h) prior PPI consumption, i) comorbidities, j) breakdown of specific comorbidities (the white number inside the bars represents the number of patients with the comorbidity).

- a) Mann-Whitney test. c, d, e, f, h, and i) Fisher's exact test. Stacked bars
- represent the percentage of patients for each parameter. ns= non-significant; \*, p

# **Blood and serum parameters**

- We also analyzed the patients' blood counts and serum parameters that were
- measured on the day of fecal sample collection.
- We observed a significant increase in the number of leukocytes (Fig. 3 a) and
- platelets (Fig. 3 j) in patients infected with *C. difficile*. When analyzing the count of
- lymphocytes, monocytes and neutrophils individually between both patient
- 263 populations, although an increase was evident, we did not find significant
- 264 differences (Fig. 3 b, c and d). However, it is important to note that CDI+ patients
- 265 had increased at least two of these leukocyte populations compared to CDI-
- patients at the time of diagnosis (**Fig. 3 e, f and g**). Although some studies have
- 267 highlighted that an elevated white blood cell (WBC) count is frequently observed in
- the context of CDI <sup>72</sup> <sup>73</sup> <sup>74</sup>, little has been explored in using elevated WBC count as
- a predictor of this infection. In this regard, we agree with Vargas et al. <sup>75</sup> in that the
- total leukocyte count alone is not a specific indicator for CDI. Previous work
- evaluating platelet count in CDI episodes reported controversial results, assigning
- them both a beneficial and detrimental role in relation to clinical symptoms 76-85.
- We have recently shown that platelets bind to *C. difficile* and promote its uptake by
- 274 human macrophages using macropinocytic pathways <sup>86</sup>. Therefore, we consider
- that platelets in CDI could be fundamental for the resolution of the infection and
- that further studies are needed to unravel their role during CDI.
- 277 Regarding the rest of the blood parameters evaluated, while a significant decrease
- in basophils count was observed (Fig. 3 h), the eosinophil count was not affected
- by the presence of *C. difficile* (Fig. 3 i). To the best of our knowledge, to date there
- are no reports on the role of basophils in CDI. Nevertheless, the potential role of
- <sup>281</sup> CCL-5, a basophilic recruiter chemokine, has been highlighted in CDI <sup>87,88</sup>
- No differences were evident for creatinine and albumin levels (Fig. 3 i and k), but
- an elevated urea concentration stood out in patients infected with *C. difficile* (Fig. 3)
- m). Moreover, the BUN (Blood Urea Nitrogen)/Creatinine ratio was significantly
- elevated in CDI patients (Fig. 3 n). Elevated BUN ratios have been associated with
- complications of CDI <sup>89</sup> as well as with higher mortality rates <sup>90</sup> and high urea levels
- were also proposed as a risk factor for severe CDI <sup>91</sup>.





Figure 3. Blood and serum parameters in CDI+ and CDI- patients.

- Number of a) Leukocytes (cells/mm³), b) lymphocytes (cells/mm³), c) monocytes (cells/mm³), d) neutrophils (cells/mm³), e) lymphocytes plus monocytes (cells/mm³), f) lymphocytes plus neutrophils (cells/mm³), g) neutrophils plus monocytes (cells/mm³), h) basophils (cells/mm³), i) eosinophils (cells/mm³) and j) platelets (cells/mm³). Levels of k) creatinine (mg/dl), l) albumin (g/dl) and m) urea (mg/dl), n) BUN (blood urea nitrogen)/creatinine ratio.
- a-i and k-n) Mann-Whitney test. j) unpaired t test. Violin plots show the distribution of the data. ns= non-significant; \*, p<0.05; \*\*, p<0.01.

# Meta-analysis

We finally performed a meta-analysis to obtain more robust and reliable conclusions about the CDI associated parameters evaluated in our cohort. We defined the selection criteria (**Fig. 4 a**) and carried out a systematic review that allowed us to select 40 independent case/control type studies (**Table 2**) from the countries shown in light grey in **Fig. 4 b**.





**Figure 4.** Flow chart of the studies and countries screened and included in the Meta-analysis.

- a) The obtained results regarding clinical and demographic characteristics of the CDI+ and CDI- patients in our cohort were contrasted against findings of other studies through a meta-analysis by RStudio package "Metafor". After initial identification, eligibility criteria were applied and 39 reports were included in the meta-analysis along with our data. CDI- patients were considered as the control group.
- b) World map showing the countries from which the studies included in the metaanalysis come (light gray). The circles contain the number of studies selected per country.

Countries	Studies			
Argentina	Lopardo, G. et al, 2015 <sup>39</sup>			
Brazil	OUR study Lopes Cançado, G. G. et al, 2018 <sup>92</sup>			
Canada	Lowe, D. O. et al, 2006 <sup>93</sup>			
	Dai, W. et al, 2020 <sup>94</sup>			
	Li, Y. et al, 2016 <sup>95</sup>			
China	Lv, Z. et al, 2014 <sup>96</sup>			
	Tang, C. et al, 2018 <sup>97</sup>			
	Zhou, F, F, et al, 2014 <sup>98</sup> Carvajal, C. et al, 2017 <sup>99</sup>			
Colombia	Salazar, C, L. et al, 2017			
Denmark	Soes, L. M. et al, 2014 101			
France	Le Monnier, A. et al, 2022 102			
Hungary	Kurti, Z. et al, 2015 <sup>103</sup>			
Iceland	Vesteinsdottir, I. et al, 2012 <sup>104</sup>			
India	ingle, IVI. et al, 2011			
lonon	ingle, IVI. et al, 2013			
Japan Mexico	Mori, N. et al, 2015 <sup>107</sup> Morfin-Otero, R. et al, 2016 <sup>108</sup>			
Poland	Czepiel, J. et al, 2014 109			
	Legenza, L. et al, 2018 110			
South Africa	Rajabally, N. et al, 2013 <sup>111</sup>			
South Korea	Han, S. H. et al, 2014 112			
Taiwan	Lee, Y. C. et al, 2012 <sup>113</sup> ; Lin			
Thailand	C. Y. et al, 2022 114 Thipmontree, W. et al, 2011 115			
Turkey	Ergen, E. K. et al, 2009 116			
Turkey	Dial, S. et al, 2005 <sup>117</sup>			
	Dial, S. et al, 2008 <sup>118</sup>			
United Kingdom	Marwick, C. A. et al, 2013 119			
	Suissa, D. et al, 2012 120			
	vviicox, ivi. n. et al, 2008			
	Baxter, R. et al, 2008 <sup>122</sup> Haddad, F. G. et al, 2019 <sup>123</sup>			
	Kuntz, J. L. et al, 2019			
United Otates	Kutty, P. K. et al, 2010 <sup>125</sup>			
United States	Kwon, S. et al, 2017 <sup>126</sup>			
	Naggie, S. et al, 2011 127			
	Tabak, P. Y. et al, 2015 <sup>128</sup>			
	Tartof, S. Y. et al, 2015 129			

Table 2. Countries and studies included in the meta-analysis.

The effects for each of the variables evaluated in the meta-analysis are summarized in **Table 3**.

330	<b>RISK PREDICTOR</b>	OR
	Age	1,19 **
331	Biological sex	0,89 *
	Prior ATB consumption	3,02 ***
332	Prior PPI consumption	1,29 ns
	Prior hospitalization	2,45 ***
333	Prior CDI	1,76 ns
	WBC (10 <sup>9</sup> cel/mm <sup>3</sup> )	1,35 *
334	Platelets (10 <sup>9</sup> cel/ mm <sup>3</sup> )	1,54 ns
	Comorbidities	
335	Diabetes <i>mellitus</i>	1,26 ns
	Heart disease	1,41 *
336	Kidney disease	2,23 ***
	HIV	1,00 ns
337		

**Table 3.** Summary of risk predictors from the meta-analysis.

The dataset included 11,596 individuals with CDI and 536,467 matched controls **(Table 4)**. Overall, the distribution of biological sex was 40.06% male vs. 59.94% female, being 44.33% vs. 55.67% in the CDI+ population and 39.98% vs. 60.02% in the control group. The demographic parameters Age (OR= 1.19; 95% CI, 1.06 to 1.35) and Biological Sex (OR= 0.89; 95% CI, 0.81 to 0.99) obtained significant models, which implies that, globally, advanced age and female biological sex are associated with a higher risk of CDI **(Fig. 5 a and b)**.

9.11% of the included individuals were previously exposed to antibiotics and 22.18% to PPI. Both antibiotic (CDI+ 39.95% vs. CDI- 8.52%) and PPI (CDI+ 29.87% vs. CDI- 21.76%) consumption was higher among those patients infected with *C. difficile* (Table 4). In this analysis, which ignored antibiotic subclasses, we found that the pooled impact of any antibiotic exposure (OR= 3.02; 95% CI, 2.32 to 3.94) increased the risk of CDI by a multiple of 3 (Fig. 5 c). A longer duration of antibiotic therapy, as well as a greater number of antibiotics administered increase the probability of CDI <sup>70</sup>. The risk of acquiring CDI could be 8 to 10 times higher during antibiotic therapy, even three months after its completion, with the first month being the one with the highest risk <sup>130</sup>.

Regarding PPIs as risk factors for CDI, there is an arduous discussion with some reports showing around 40-71.4% of hospitalized patients received PPI therapy during hospitalization <sup>131–133</sup> and others supporting the idea that PPIs could trigger long-term adverse effects trough changes on the microbiota composition <sup>134,135</sup>. In our meta-analysis, there was no evidence of the impact of PPI on CDI risk **(Fig. 5 d)**.

Previous hospitalization emerged as the second most influential predictor for CDI risk (OR= 2.46; 95% CI, 1.90 to 3.17) **(Fig. 5 e)**. Among the CDI+ patients included in the meta-analyses, 27.88% had been hospitalized prior to diagnosis **(Table 4)** while only 16.80% in the control group.

Previous episodes of CDI are widely reported as a risk factor for subsequent cases and/or recurrences in patients. However, in this meta-analysis previous CDI was not a predictor of risk (**Fig. 5 f**) which could be attributed to the fact that only 4 of the 40 included studies provided this type of data <sup>56,103,120,123</sup>. Actually, when evaluating the Forest Plot for this variable in detail, the studies show the same trend as our epidemiological study when considering previous CDI as a risk factor.

When evaluating comorbidities, both heart diseases (OR= 1.41; 95% CI, 1.02 to 1.94) and chronic kidney disease (OR= 2.23; 95% CI, 1.38 to 3.61) exhibited models with significant effects (**Fig. 5 g and h**), indicating that these pathologies increase the risk of CDI. The rest of the tested comorbidities were not associated with a higher risk of infection (**Fig. 5 i and j**). The presence of comorbidities has been widely reported as a condition that facilitates colonization and infection by *C. difficile* <sup>136</sup>. A previous meta-analysis found IBD, diabetes, leukemia or lymphoma, kidney failure and solid cancer as the CDI risk-related comorbidities <sup>137</sup>.

Finally, blood parameters were analyzed. Increased leukocytes count was also a potential predictor of CDI according to our comparative analysis (OR= 1.36; 95% CI, 1.05 to 1.75) (Fig. 5 k). Although the number of platelets did not show a statistically significant effect (Fig. 5 I), it is important to note that only 2 studies apart from ours evaluated this parameter.

		CDI+	CDI-	TOTAL
Nº of individuals		11596	536467	548467
Sex	Male	44.33%	39.98%	40.06%
	Female	55.67%	60.02%	59.94%
Prior ATB consumption	With	39.95%	8.52%	9.11%
	Without	60.05%	91.48%	90.89%
Prior PPI consumption	With	29.87%	21.76%	22.18%
	Without	70.13%	78.24%	77.82%
Prior hospitalization	With	27.88%	16.80%	17.07%
	Without	72.12%	83.20%	82.93%

**Table 4.** Meta-analysis dataset.




Figure 5 Forest plots of risk predictors.

- Forest plots representative of each variable evaluated in the meta-analysis. a) Age,
- b) biological sex, c) previous ATB consumption, d) previous PPI consumption, e)
- prior hospitalization, f) prior CDI, g) heart disease, h) chronic kidney disease, i)
- diabetes *mellitus*, j) HIV, k) white blood cells (WBC) count (cells/mm<sup>3</sup>), l) platelets
- 401 count (cells/mm<sup>3</sup>).
- 402 A REML (Random Effect Maximum Likelihood, gray diamond) random effects
- model was applied. Models with p<0.05 (OR/SMD  $\pm$  CI values less or greater than
- 1) were considered as potential risk predictors for CDI. Black diamonds represent
- 405 the means of each of the variables in each study. Bars indicate the lower and
- 406 upper confidence extremes. Our study (white diamond) is mentioned as OUR
- 407 *STUDY.*

408 OR= odds ratio. SMD= standard media deviation. CI= confidence interval

# Conclusions

- We have defined risk factors associated with CDI and detected modulations in
- different blood parameters in our study cohort in Argentina. We have also explored
- 413 the relevance of our findings at a global level by a systematic review and meta-
- analysis. Our results emphasize the need to detect *C. difficile* as a causal agent of
- infectious diarrhea in a country where testing is not standardized or routinely
- performed in the health institutions. Our report provides valuable insights that could
- 417 contribute to a more efficient surveillance of CDI, diagnosis and follow-up of
- 418 patients.

410

419

# **Author contributions**

- 420 Conceptualization: all authors
- 421 Formal analysis: AMB, NDM, JC, SP, LSM and REHDP.
- 422 Funding acquisition: AMB, SP, REHDP and VP.
- 423 Investigation: AMB, NDM, SP, REHDP and VP.
- 424 Methodology: all authors.
- 425 Software: NDM and REHDP.
- 426 Supervision: REHDP and VP.
- Writing: AMB wrote the original draft. All authors contributed to the review & editing
- 428 of this manuscript.

#### 429 Role of the funding source

- This work was supported by Universidad Nacional del Noroeste de la Provincia de
- Buenos Aires [grant numbers SIB 0618/2019, SIB 2113/2022 and "Proyectos de
- Investigación Interdisciplinarios de la UNNOBA" Res. CS 2190/2022, to VP].
- 433 Agencia Nacional de Promoción Científica y Tecnológica, Fondo para la
- 434 Investigación Científica y Tecnológica [ANPCyT-FONCyT, grant numbers PICT A
- 2017-1896 and PICT-2021-I-A-01119 to VP; PICT 2018-03084 IB to RHDP, PICT-
- 436 2021-I-INVI-00584 to AB and PICT-2021-I-INVI-00208 to SPI. UNNOBA FONCyT
- 437 [grant number PICTO 2019-00007 to RHDP and VP]. Consejo Nacional de
- 438 Investigaciones Científicas y Técnicas [CONICET, grant number PIP 2021
- 439 11220200103137CO to VP and RHDP].

# Acknowledgements

- We thank all the patients who voluntarily participated of this study. We also thank
- Natalia Menite, Lucia Romano and Gastón Villafañe for their technical assistance.
- We acknowledge the laboratory personnel, medical staff and biochemists who
- have collaborated in the collection of samples and data during the study period of
- this report. Finally, we thank Flaticon for the icons used in the graphical abstract of
- 446 this work.

# References

- 448 1. Brazier JS. . 1998;47–57.
- 2. Zhang S, Palazuelos-Munoz S, Balsells EM, et al. . *BMC Infect Dis*;16 . Epub ahead of print 2016. DOI: 10.1186/s12879-016-1786-6.
- 451 3. Center for Disease Control and Prevention. . *CDC*;10 . Epub ahead of print 2019. DOI: 10.1186/s13756-020-00872-w.
- 453 4. Smits WK, Lyras D, Lacy DB, et al. . DOI: 10.1038/nrdp.2016.20.
- 5. Feuerstadt P, Theriault N, Tillotson G. . BMC Infect Dis. 2023;23:1–8.
- 455 6. Di X, Bai N, Zhang X, et al. . Brazilian J Infect Dis. 2015;19:339–349.
- 456 7. Bainum TB, Reveles KR, Hall RG, et al. . *Microorganisms*. 2023;11:1–22.
- 457 8. Phanchana M, Harnvoravongchai P, Wongkuna S, et al. . *World J*458 *Gastroenterol.* 2021;27:7210–7232.
- 459 9. Burke KE, Lamont JT. . Gut Liver. 2014;8:1-6.
- 460 10. Freeman J, Bauer MP, Baines SD, et al. . *Clinical Microbiology Reviews*. 2010;23:529–549.
- 11. Goorhuis A, Bakker D, Corver J, et al. . *Clin Infect Dis.* 2008;47:1162–1170.
- 12. Chitnis AS, Holzbauer SM, Belflower RM, et al. . *JAMA Intern Med.* 2013;173:1359–1367.
- 13. Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, et al. . *Obstet Gynecol.* 2018;131:387–391.
- 467 14. Gupta A, Khanna S. . *Infect Drug Resist*. 2014;7:63–72.
- 468 15. Alice Y. Guh, MD, MPH and Preeta K. Kutty, MD M. . *Physiol Behav*. 2019;169:248–256.
- 16. Lawler AJ, Lambert PA, Worthington T. . *Trends Microbiol*. 2020;28:744–752.
- 472 17. Paredes-Sabja D, Shen A, Sorg JA. . *Trends Microbiol.* 2014;22:1–15.
- 473 18. Hernández Del Pino RE, Barbero AM, Español LÁ, et al. . *J Leukoc Biol*. 2021;109:195–210.
- 475 19. Lim SC, Knight DR, Riley T V. . *Clin Microbiol Infect.* 2020;26:857–863.
- 476 20. Donskey CJ. . Clin Infect Dis. 2010;50:1458–1461.
- 21. Dicks LMT. . *Microorganisms*;11 . Epub ahead of print 2023. DOI:
- 478 10.3390/microorganisms11092161.
- Czepiel J, Dróżdż M, Pituch H, et al. . Eur J Clin Microbiol Infect Dis Off
   Publ Eur Soc Clin Microbiol. 2019;38:1211–1221.

- 481 23. Huang CH, Tseng YH, Tsai WS, et al. . *Infect Dis Ther* . Epub ahead of print 2024. DOI: 10.1007/s40121-024-00922-5.
- 483 24. Song JH, Kim YS. . Gut Liver. 2019;13:16–24.
- 484 25. Nitzan O, Elias M, Chazan B, et al. . *World J Gastroenterol.* 2013;19:7577–485 7585.
- 486 26. Qu H-Q, Jiang Z-D. . Diabetes Res Clin Pract. 2014;105:285–294.
- 487 27. Dudzicz S, Wiecek A, Adamczak M. . *J Clin Med.* 2021;10:1–13.
- 28. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. . *World J Emerg Surg*. 2015;10:1–23.
- 490 29. Khanna S, Pardi DS. . Mayo Clin Proc. 2012;87:1106–1117.
- 491 30. Curcio D, Cané A, Fernández FA, et al. . *Infect Dis Ther*. 2019;8:87–103.
- 492 31. Roldan GA, Cui AX, Pollock NR. . *J Clin Microbiol*;56 . Epub ahead of print March 2018. DOI: 10.1128/JCM.01747-17.
- 494 32. Acuña-Amador L, Quesada-Gómez C, Rodríguez C. . *Anaerobe*;74 . Epub ahead of print 2022. DOI: 10.1016/j.anaerobe.2022.102547.
- 496 33. Crobach MJT, Planche T, Eckert C, et al. . *Clin Microbiol Infect*. 2016;22:S63–S81.
- 498 34. Johnson S, Lavergne V, Skinner AM, et al. . *Clin Infect Dis.* 2021;73:e1029– e1044.
- 500 35. Viechtbauer W. . J Stat Softw. 2010:36:1–48.
- 501 36. Fernandez Canigia L, Nazar J, Arce M, et al. . *Rev Argent Microbiol.* 2001;33:101–107.
- 37. Legaria MC, Lumelsky G, Rosetti S. . *Anaerobe*. 2003;9:113–116.
- 504 38. Goorhuis A, Legaria MC, van den Berg RJ, et al. . *Clin Microbiol Infect*. 2009;15:1080–1086.
- 506 39. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. . *Brazilian J Infect Dis*. 2015;19:8–14.
- 508 40. Bartlett JG, Gerding DN. . *Clinical Infectious Diseases*;46 . Epub ahead of print January 2008. DOI: 10.1086/521863.
- 510 41. Pan L, Mu M, Yang P, et al. . *Am J Gastroenterol*. 2020;115:766–773.
- 511 42. Granata G, Petrosillo N, Al Moghazi S, et al. . *Anaerobe*. 2022;74:102484.
- Huttner BD, Catho G, Pano-Pardo JR, et al. . *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2020;26:808–810.
- 514 44. Chen N, Zhou M, Dong X, et al. . *Lancet (London, England)*. 2020;395:507–

- **515 513**.
- 516 45. Adams-Sommer V, Fu Y, Grinspan LT, et al. . *Infect Control Hosp Epidemiol*.
- 517 2021;42:1165–1166.
- 518 46. Laszkowska M, Kim J, Faye AS, et al. . *Dig Dis Sci.* 2021;66:4398–4405.
- 519 47. Hawes AM, Desai A, Patel PK. . Anaerobe. 2021;70:102384.
- 520 48. Luo M, Liu Y, Wu P, et al. . 8 . Epub ahead of print 2017. DOI:
- 521 10.3389/fphys.2017.00822.
- 522 49. Khanna S, Kraft CS. . Future Microbiol. 2021;16:439–443.
- 523 50. Tariq R, Saha S, Furqan F, et al. . *Mayo Clin Proc.* 2020;95:1632–1648.
- 524 51. Louie TJ, Cannon K, Byrne B, et al. . Clin Infect Dis an Off Publ Infect Dis
- 525 Soc Am. 2012;55 Suppl 2:S132-42.
- 526 52. Guh AY, Mu Y, Winston LG, et al. . *N Engl J Med*. 2020;382:1320–1330.
- 527 53. Gentry CA, Williams RJ 2nd, Campbell D. . Diagn Microbiol Infect Dis.
- 528 2021;100:115308.
- 529 54. McDermott LA, Thorpe CM, Goldstein E, et al. . Open Forum Infect Dis.
- 530 **2022;9:ofac492.1299**.
- 531 55. Dingle KE, Didelot X, Quan TP, et al. . Lancet Infect Dis. 2017;17:411–421.
- 532 56. Wilcox MH, Shetty N, Fawley WN, et al. . Clin Infect Dis. 2012;55:1056-
- 533 **1063**.
- 534 57. Khanna S, Pardi DS, Aronson SL, et al. . Am Coll Gastroenterol;107.
- 535 58. European Centre for Disease Prevention and Control. . *Annu Epidemiol Rep*
- 536 Commun Dis Eur. 2016;40:335–348.
- 537 59. Carlson TJ. Blasingame D. Gonzales-Luna AJ. et al. . *Anaerobe*.
- 538 2020;62:102142.
- 539 60. Kincaid SE. . Consult Pharm J Am Soc Consult Pharm. 2010;25:834–836.
- 540 61. Owens RC. . Drugs. 2007;67:487-502.
- 62. Bassaris HP, Lianou PE, Legakis NJ, et al. . *Med Microbiol Immunol*.
- 542 **1984;173:49–55**.
- 543 63. Nakamura S, Mikawa M, Nakashio S, et al. . *Microbiol Immunol*.
- 544 **1981;25:345–351**.
- 545 64. Bacon AE, Fekety R. . Diagn Microbiol Infect Dis. 1994;18:205–209.
- 546 65. Simor AE, Bradley SF, Strausbaugh LJ, et al. . Infect Control Hosp
- 547 *Epidemiol.* 2002;23:696–703.
- 548 66. Guerrero DM, Nerandzic MM, Jury LA, et al. . Am J Infect Control.

- 549 **2012;40:556–558**.
- 550 67. Edwards AN, Karim ST, Pascual RA, et al. . Front Microbiol. 2016;7:1698.
- 551 68. Clark T, Wiselka M. . Clin Med. 2008;8:544–547.
- 552 69. Schroeder MS. . *Am Fam Physician*. 2005;71:921–928.
- 553 70. Hessen MT. . Ann Intern Med. 2010;153:ITC41-15; quiz ITC416.
- 554 71. Dubberke ER, Wertheimer AI. . *Infect Control Hosp Epidemiol*. 2009;30:57–555 66.
- 556 72. Wanahita A, Goldsmith EA, Marino BJ, et al. . *Am J Med*. 2003;115:543–546.
- 557 73. Wanahita A, Goldsmith EA, Musher DM. . Clin Infect Dis an Off Publ Infect 558 Dis Soc Am. 2002;34:1585–1592.
- 559 74. Bulusu M, Narayan S, Shetler K, et al. . *Am J Gastroenterol.* 2000;95:3137–3141.
- 561 75. Vargas E, Apewokin S, Madan R. . *Anaerobe*. 2017;45:101–105.
- 562 76. Mihăilă RG, Cătană C, Olteanu AL, et al. . *Biomarkers*. 2019;24:389–393.
- 563 77. Buchrits S, Gafter-Gvili A, Bishara J, et al. . *J Clin Med*;10 . Epub ahead of print July 2021. DOI: 10.3390/jcm10132957.
- 565 78. Lee DY, Chung EL, Guend H, et al. . *Ann Surg.* 2014;259:148–156.
- 79. Byrn JC, Maun DC, Gingold DS, et al. . *Med Hist*. 2012;143:150–154.
- 80. Nseir W, Khamisy-Farah R, Amara A, et al. . *Isr Med Assoc J.* 2019;21:658–661.
- 81. Allegretti JR, Marcus J, Storm M, et al. . Dig Dis Sci. 2020;65:1761–1766.
- 570 82. Zhao L, Luo Y, Bian Q, et al. . Infect Drug Resist. 2020;13:171–181.
- 571 83. Pant C, Madonia PN, Jordan P, et al. . *J Investig Med.* 2009;57:40–42.
- 572 84. Yan D, Chen Y, Lv T, et al. . *J Med Microbiol*. 2017;66:1483–1488.
- 85. Phanchana M, Phetruen T, Harnvoravongchai P, et al. . *Sci Rep.* 2020;10:1–8.
- 575 86. Barbero AM, Hernández Del Pino RE, Fuentes F, et al. . 2024;1–14.
- 576 87. Rao K, Erb-Downward JR, Walk ST, et al. . *PLoS One*. 2014;9:e92578.
- 88. Abhyankar MM, Ma JZ, Scully KW, et al. . Am Soc Microbiol. 2020;11:1–10.
- 89. Abou Chakra CN, McGeer A, Labbe AC, et al. . Clin Infect Dis.
- 579 2015;61:1781–1788.
- 580 90. Sartelli M, Di Bella S, McFarland L V., et al. . *World J Emerg Surg.* 2019;14:1–29.

- 582 91. Bermejo Boixareu C, Tutor-Ureta P, Ramos Martínez A. . *Rev Esp Geriatr* 683 *Gerontol.* 2020;55:225–235.
- 584 92. Lopes Cançado GG, Silveira Silva RO, Rupnik M, et al. . *Anaerobe*. 2018;54:65–71.
- 586
   93. Lowe DO, Mamdani MM, Kopp A, et al. Proton Pump Inhibitors and
   587 Hospitalization for Clostridium Difficile-Associated Disease: A Population 588 Based Study.
- 94. Dai W, Yang T, Yan L, et al. . *BMC Infect Dis*;20 . Epub ahead of print April
   2020. DOI: 10.1186/s12879-020-05014-6.
- 591 95. Li Y, Huang Y, Li Y, et al. . Pakistan J Med Sci. 2016;32:736–741.
- 592 96. Lv Z, Peng GL, Su JR. . *Brazilian J Med Biol Res.* 2014;47:1085–1090.
- 593 97. Tang C, Li Y, Liu C, et al. . Am J Infect Control. 2018;46:285–290.
- 594 98. Zhou FF, Wu S, Klena JD, et al. . *Eur J Clin Microbiol Infect Dis*.
   595 2014;33:1773–1779.
- 596 99. Carvajal C, Pacheco C, Jaimes F. . *Biomedica*. 2017;37:53-61.
- 597 100. Salazar CL, Reyes C, Atehortua S, et al. . *PLoS One*;12 . Epub ahead of print September 2017. DOI: 10.1371/journal.pone.0184689.
- 101. Soes LM, Holt HM, Böttiger B, et al. . *Epidemiol Infect*. 2014;142:1437–1448.
- 102. Le Monnier A, Candela T, Mizrahi A, et al. . J Hosp Infect. 2022;129:65–74.
- 103. Kurti Z, Lovasz BD, Mandel MD, et al. . World J Gastroenterol.
   2015;21:6728–6735.
- 104. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, et al. . *Eur J Clin Microbiol Infect Dis.* 2012;31:2601–2610.
- 105. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol.* 2011;30:89–93.
- 106. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2013;32:179–183.
- 107. Mori N, Aoki Y. . *J Infect Chemother*. 2015;21:864–867.
- 108. Morfin-Otero R, Garza-Gonzalez E, Aguirre-Diaz SA, et al. . *Brazilian J Infect Dis*. 2016;20:8–13.
- 109. Czepiel J, Biesiada G, Brzozowski T, et al. . *J Physiol Pharmacol an Off J Polish Physiol Soc.* 2014;65:695–703.
- 110. Legenza L, Barnett S, Rose W, et al. . *BMJ Glob Heal*;3 . Epub ahead of print July 2018. DOI: 10.1136/bmjgh-2018-000889.
- 111. Rajabally N, Pentecost M, Pretorius G, et al. . South African Med J.


- 617 2013;103:168–172.
- 112. Han SH, Kim H, Lee K, et al. . *J Med Microbiol*. 2014;63:1542–1551.
- 113. Lee YC, Wang JT, Chen AC, et al. . *J Microbiol Immunol Infect*.
   2012;45:287–295.
- 114. Lin C-Y, Cheng H-T, Kuo C-J, et al. . *Microbiol Spectr*,10 . Epub ahead of print August 2022. DOI: 10.1128/spectrum.00486-22.
- Thipmontree W, Kiratisin P, Manatsathit S, et al. Epidemiology of Suspected Clostridium difficile-Associated Hospital-Acquired Diarrhea in Hospitalized Patients at Siriraj Hospital. 2011.
- 116. Ergen EK, Akalin H, Yilmaz E, et al. . Med Mal Infect. 2009;39:382-387.
- 117. Dial S, Delaney JAC, Barkun AN, et al. . JAMA. 2005;294:2989–2995.
- 118. Dial S, Kezouh A, Dascal A, et al. . C Can Med Assoc J. 2008;179:767–772.
- 119. Marwick CA, Yu N, Lockhart MC, et al. . *J Antimicrob Chemother*.
   2013;68:2927–2933.
- 631 120. Suissa D, Delaney JAC, Dial S, et al. . *Br J Clin Pharmacol.* 2012;74:370–632 375.
- 633 121. Wilcox MH, Mooney L, Bendall R, et al. . *J Antimicrob Chemother*. 2008;62:388–396.
- 635 122. Baxter R, Ray GT, Fireman BH. . *Infect Control Hosp Epidemiol*. 2008;29:44–50.
- 123. Haddad FG, Zaidan J, Polavarapu A, et al. . *Z Gastroenterol*. 2019;57:1183–
   1195.
- 639 124. Kuntz JL, Chrischilles EA, Pendergast JF, et al. . *BMC Infect Dis*;11 . Epub 640 ahead of print July 2011. DOI: 10.1186/1471-2334-11-194.
- 125. Kutty PK, Woods CW, Sena AC, et al. . *Emerg Infect Dis.* 2010;16:197–204.
- 126. Kwon SS, Gim JL, Kim MS, et al. . *Anaerobe*. 2017;48:42–46.
- 127. Naggie S, Miller BA, Zuzak KB, et al. . *Am J Med*;124 . Epub ahead of print
   March 2011. DOI: 10.1016/j.amjmed.2010.10.013.
- 128. Tabak YP, Johannes RS, Sun X, et al. . *Infect Control Hosp Epidemiol*. 2015;36:695–701.
- 129. Tartof SY, Rieg GK, Wei R, et al. . *Infect Control Hosp Epidemiol*. 2015;36:1409–1416.
- 130. Hensgens MPM, Goorhuis A, Dekkers OM, et al. . *J Antimicrob Chemother*. 2012;67:742–748.
- 131. Nardino RJ, Vender RJ, Herbert PN. . Am J Gastroenterol. 2000;95:3118–

3122. 652

- 132. Herzig SJ, Howell MD, Ngo LH, et al. . JAMA. 2009;301:2120-2128. 133. Pham CQD, Regal RE, Bostwick TR, et al. . Ann Pharmacother. 654
- 2006;40:1261-1266. 655


653


- 134. Freedberg DE, Lebwohl B, Abrams JA. . Clin Lab Med. 2014;34:771–785. 656
- 135. Singh A, Cresci GA, Kirby DF. . Nutr Clin Pract Off Publ Am Soc Parenter 657 Enter Nutr. 2018;33:614-624. 658
- 659 136. van Prehn J, Reigadas E, Vogelzang EH, et al. . Clin Microbiol Infect. 660 2021;27:S1-S21.
- 137. Furuya-Kanamori L, Stone JC, Clark J, et al. . Infect Control Hosp Epidemiol. 661 2015;36:132-141. 662



43.59% Hospital-acquired

= 23.08% Community-acquired associated to healthcare environments







Identified studies in PubMed (3,701 articles), Google Scholar (229 articles) and SciSpace.

仚

records", "Epidemiology", "Cases and controls study"

blMed 🏺

102 studies assessed for Eligibility 40 studies included in Meta-analysis

Included

Package "Metafor"

Search terms: "CDI", "C. difficile", "Clinical

Inclusion criteria

- Over 18 years old Cases (patients with diarrhea and a positive CDI diagnosis by
- EIA, PCR and/or toxigenic culture)


63 studies excluded


**心** 


仚


Eligibility

 Controls (patients with disarrhee and a negative CDI (diagnosis)
 Variables of interest (Age, Biological sex, Use of antibiotics in the previous 3 months. Use of proton pump inhibitions, Leukocyte count, Platelet count, Presence of comorbidities (Diabetes mellibu, Heart disease, Kidney disease, HIVI)










#### SANITARY REGION III





- Hospital Interzonal General de Agudos Abraham Piñeyro
   C.P.A.: Provincial Center for Addiction Care



\*clinical evaluation is required in all cases

